Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
Protagonist Therapeutics (PTGX) announced that its board has authorized a share repurchase program for up to $300 million of outstanding common stock. The company plans to fund buybacks from existing cash, cash equivalents and marketable securities, and from royalties and other payments under collaboration agreements with Takeda for MIMRYLO™ (rusfertide) and Johnson & Johnson for ICOTYDE™ (icotrokinra). As of June 30, 2026, Protagonist held $849.5 million in cash, cash equivalents and marketable securities, excluding a $200 million opt-out payment and a $75 million milestone earned from Takeda in August 2026, which are expected in Q4 2026. Repurchases are discretionary, may occur via open market or other transactions, and the program can be modified, suspended or discontinued at any time.
Protagonist Therapeutics (PTGX) will participate in two investment bank conferences in New York in September 2026, featuring fireside chats with President and CEO Dinesh V. Patel, Ph.D.
The company presents at the Citi Biopharma Back to School Conference on September 9, 2026 at 10:40 A.M. ET and at the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 10:20 A.M. ET, with webcasts and one-year replays available via its Investor Relations webpage.
Protagonist Therapeutics (NASDAQ:PTGX) reported that partner Takeda received U.S. FDA approval for MIMRYLO (rusfertide), the first and only hepcidin mimetic peptide therapy for treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO, a weekly subcutaneous injection, directly targets red blood cell overproduction by mimicking hepcidin to control hematocrit and help restore iron balance.
Approval is based on the Phase 3 VERIFY trial, where 76.9% of patients on MIMRYLO plus standard of care achieved a clinical response during Weeks 20–32 versus 32.9% on placebo. FDA approval triggers $275 million in payments to Protagonist (a $200 million opt-out fee and a $75 million approval milestone), with up to an additional $875 million in potential milestones and tiered worldwide net sales royalties of 14%–29% (about 21% weighted-average at $1.5 billion in annual sales). This is Protagonist’s second FDA-approved first-in-class medicine in 2026, alongside ICOTYDE, further validating its peptide platform and partnership model.
Protagonist Therapeutics (Nasdaq: PTGX) granted inducement equity awards on August 17, 2026 to two newly hired employees under its Amended and Restated Inducement Plan. The grants comprise options to purchase an aggregate 5,675 shares at an exercise price of $155.10 and RSUs for 1,500 shares, with four-year vesting schedules. The awards were approved by the compensation committee as material inducements in line with Nasdaq Rule 5635(c)(4).
Protagonist describes itself as a discovery-through-late-stage biopharmaceutical company. Its oral peptide ICOTYDE, licensed to a Johnson & Johnson company, launched in the U.S. in March 2026 for plaque psoriasis and is in Phase 3 for multiple immune indications, while rusfertide, licensed to Takeda, has an NDA under FDA priority review for polycythemia vera.
Protagonist Therapeutics (Nasdaq: PTGX) reported second quarter 2026 license and collaboration revenue of $213.5 million, up from $5.5 million a year earlier, driven mainly by recognition of a $200 million rusfertide opt-out payment from Takeda and related development services. Net income was $162.8 million, versus a net loss of $34.8 million in Q2 2025. Cash, cash equivalents and marketable securities rose to $849.5 million as of June 30, 2026, from $646.0 million at year-end 2025.
According to Protagonist Therapeutics, Takeda now holds exclusive global rights to rusfertide, with Protagonist eligible for an additional $200 million opt-out fee, a $75 million milestone upon potential FDA approval, up to $775 million in sales milestones, and tiered royalties of 14%–29%. ICOTYDE, approved in March 2026 and in its first full commercial quarter, previously triggered a $50 million milestone and carries potential future milestones up to $580 million plus 6%–10% tiered royalties. The company highlighted advancement of wholly owned programs, including a planned Phase 2b psoriasis program for PN‑881 in early Q1 2027 and multiple obesity and hematology candidates entering Phase 1, and it expects research and development expenses to rise significantly in the second half of 2026.
Protagonist Therapeutics (Nasdaq: PTGX) granted inducement equity awards on July 31, 2026 to two newly hired employees under its Amended and Restated Inducement Plan. The awards total options to purchase 7,300 shares and 1,975 RSUs, with an exercise price of $136.64 per share, equal to the July 31 Nasdaq closing price.
Options vest over four years (25% after one year, then monthly over three years), and RSUs vest in four equal annual installments. The compensation committee approved the grants as material inducements to employment in line with Nasdaq Rule 5635(c)(4). Protagonist highlights its peptide-based pipeline, including ICOTYDE, launched in the U.S. in March 2026 for plaque psoriasis and in Phase 3 for additional indications, and rusfertide, for which an NDA for polycythemia vera is under FDA priority review.
Protagonist Therapeutics (Nasdaq: PTGX) reported that on July 15, 2026, it granted equity inducement awards to three recently hired employees under its Amended and Restated Inducement Plan, originally adopted May 29, 2018 and amended in 2020 and 2022.
The employees received, in aggregate, options for 12,600 shares of common stock and RSUs for 3,330 shares. The stock options have an exercise price of $135.46, equal to the July 15, 2026 Nasdaq Global Market closing price. Options vest over four years (25% after one year, then monthly over three years), while RSUs vest 25% annually over four years. The compensation committee approved these awards as material inducements to employment in accordance with Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (Nasdaq: PTGX) granted stock-based inducement awards on June 30, 2026 to three new employees under its Inducement Plan. Awards include options for 8,650 shares and 2,275 RSUs at an exercise price of $122.58 per share.
Options vest over four years, with 25% after one year and the rest monthly over three years. RSUs vest in four equal annual installments. The compensation committee approved these grants as material inducements under Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (Nasdaq:PTGX) granted equity inducement awards to three new employees on June 15, 2026, under its Amended and Restated Inducement Plan.
The grants total 14,800 stock options at a $112.46 exercise price and 3,900 RSUs, with four-year vesting schedules, approved under Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics (PTGX) will present four abstracts on rusfertide in polycythemia vera at the 2026 European Hematology Association Congress in Stockholm, June 11-14, 2026.
Data span the Phase 3 VERIFY trial and long-term Phase 2 REVIVE and THRIVE extension studies, covering efficacy, safety, cytoreductive therapy use, thromboembolic and progression events, and patient-reported outcomes.